CD276 and brain cancer: Chimeric antigen receptor (CAR) T cell clinical trials targeting GBM antigens such as EGFRvIII,7 IL13Rα2,8 in adults, and also B7-H3 (CD276) for diffuse intrinsic pontine glioma (DIPG)9 and human epidermal growth factor receptor 2 (HER2) in central nervous system (CNS) tumors, including DMG,10 have confirmed the safety of these cellular therapies in treating brain cancer.